Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | March 29, 2018 | April 02, 2018 |
| WELLS FARGO & COMPANY/MNWFC · Entity 2824 | Director | April 01, 2013 | April 02, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 29, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 27,375.7941 |
Reported balance
After 2018-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 205.4266 · Balance 27,375.7941 F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.
F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.
F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.
WELLS FARGO & COMPANY/MN
Report date April 01, 2013 · Filed April 02, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 61,962.9483 |
Reported balance
After 2013-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-04-01 · Grant · Acquired 1,651.7736 · Balance 61,962.9483 F2: Conversion price is 1-for-1 F3: Deferred compensation shares payable in installments depending upon director's election. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | Direct | 1,122.938 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,122.938 F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | IndirectThrough Family Trust | 1,000 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013.
F2: Conversion price is 1-for-1
F3: Deferred compensation shares payable in installments depending upon director's election.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2006 Filed Jul 6, 2006 18:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 472.49 | $59.26 Strike: $59.26 | $27,999.76 |
DisclosureSEC source: 0001179110-06-014742 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472.49 Underlying: Common Stock · 472.49 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over ten years when the reporting person reaches the age of 75. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over ten years when the reporting person reaches the age of 75. Read SEC document |
| July 01, 2006 Filed Jul 3, 2006 21:09 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 337.6565 | $67.08 | $22,650.00 |
DisclosureSEC source: 0001193833-06-000118 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,043.5793 Underlying: Common Stock, $1 2/3 par value · 337.6565 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Payable in 10 installments beginning July 1 following cessation of board membership F2 · derivative.expiration_date: Payable in 10 installments beginning July 1 following cessation of board membership Read SEC document |
| May 10, 2006 Filed May 12, 2006 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $57.35 | $0.00 |
DisclosureSEC source: 0001179110-06-010648 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2016-05-10 F1 · kind: Options are granted as part of the annual compensation to non-employee members of the Board of Directors and are immediately exercisable on date of grant. Read SEC document |
| April 25, 2006 Filed Apr 27, 2006 19:52 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantDirector Stock Option · Derivative | 3,329 | $0.00 Strike: $65.10 | $0.00 |
DisclosureSEC source: 0001193833-06-000085 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,329 Underlying: Common Stock, $1 2/3 par value · 3,329 shares Expires 2016-04-25 Read SEC document |
| April 25, 2006 Filed Apr 27, 2006 19:52 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,498 | $65.10 | $97,519.80 |
DisclosureSEC source: 0001193833-06-000085 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,692.661 Underlying: Common Stock, $1 2/3 par value · 1,498 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Payable in 10 installments beginning July 1 following cessation of board membership F2 · derivative.expiration_date: Payable in 10 installments beginning July 1 following cessation of board membership Read SEC document |
| April 25, 2006 Filed Oct 3, 2006 22:37 UTC Amendment | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 999 | $65.10 | $65,034.90 |
DisclosureSEC source: 0001193833-06-000154 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999 Underlying: Common Stock, $1 2/3 par value · 999 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F3 · shares: Form originally reported the purchase of 1,498 phantom stock units on April 25, 2006, through the deferral of two director's formula stock awards. The deferral of one of those awards, representing 499 phantom stock units, was made in error. That award is now shown on Table I as 499 shares of Common Stock. F2 · derivative.exercise_date: Payable in 10 installments beginning July 1 following cessation of board membership. F2 · derivative.expiration_date: Payable in 10 installments beginning July 1 following cessation of board membership. F3 · derivative.underlying_shares: Form originally reported the purchase of 1,498 phantom stock units on April 25, 2006, through the deferral of two director's formula stock awards. The deferral of one of those awards, representing 499 phantom stock units, was made in error. That award is now shown on Table I as 499 shares of Common Stock. F3 · balance_after: Form originally reported the purchase of 1,498 phantom stock units on April 25, 2006, through the deferral of two director's formula stock awards. The deferral of one of those awards, representing 499 phantom stock units, was made in error. That award is now shown on Table I as 499 shares of Common Stock. Read SEC document |
| April 25, 2006 Filed Oct 3, 2006 22:37 UTC Amendment | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantCommon Stock, $1 2/3 par value | 499 | $65.10 | $32,484.90 |
DisclosureSEC source: 0001193833-06-000154 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499 F3 · shares: Form originally reported the purchase of 1,498 phantom stock units on April 25, 2006, through the deferral of two director's formula stock awards. The deferral of one of those awards, representing 499 phantom stock units, was made in error. That award is now shown on Table I as 499 shares of Common Stock. F3 · balance_after: Form originally reported the purchase of 1,498 phantom stock units on April 25, 2006, through the deferral of two director's formula stock awards. The deferral of one of those awards, representing 499 phantom stock units, was made in error. That award is now shown on Table I as 499 shares of Common Stock. Read SEC document |
| April 01, 2006 Filed Apr 4, 2006 20:40 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 194.661 | $63.87 | $12,433.00 |
DisclosureSEC source: 0001193833-06-000070 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194.661 Underlying: Common Stock, $1 2/3 par value · 194.661 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Payable in 10 installments beginning July 1 following cessation of board membership F2 · derivative.expiration_date: Payable in 10 installments beginning July 1 following cessation of board membership Read SEC document |
| April 01, 2006 Filed Oct 3, 2006 22:29 UTC Amendment | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193833-06-000153 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $1 2/3 par value · 0 shares Expires not disclosed F1 · security: Form originally filed to report the purchase of 194.661 phantom stock units on April 1, 2006, through the deferral of quarterly cash retainer and meeting fees. That deferral was made in error, and this amendment is being filed to correct the original filing. F2 · derivative.exercise_price: Not applicable F2 · price: Not applicable F2 · derivative.exercise_date: Not applicable F2 · derivative.expiration_date: Not applicable F2 · ownership.direct: Not applicable Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $31.40 | $0.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · derivative · entry 12 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 24,000 shares Expires 2014-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $26.73 | $0.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · derivative · entry 11 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2014-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,500 | $54.14 | $189,490.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 10 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 491 | $54.12 | $26,572.92 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 9 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $54.10 | $10,820.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 8 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,991 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $54.09 | $16,227.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 7 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,191 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $54.08 | $27,040.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 6 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,491 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $54.07 | $162,210.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 5 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,991 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,952 | $54.06 | $646,125.12 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,991 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,057 | $54.05 | $867,880.85 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,943 Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 24,000 | $31.40 | $753,600.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2005 Filed Nov 22, 2005 22:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,000 | $26.73 | $320,760.00 |
DisclosureSEC source: 0001179110-05-021644 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2005 Filed Jul 6, 2005 01:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 634.49 | $44.13 Strike: $44.13 | $28,000.04 |
DisclosureSEC source: 0001179110-05-013741 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634.49 Underlying: Common Stock · 634.49 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable over ten years when the reporting person reaches the age of 75. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable over ten years when the reporting person reaches the age of 75. Read SEC document |
| May 10, 2005 Filed May 12, 2005 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $38.87 | $0.00 |
DisclosureSEC source: 0001179110-05-009689 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2015-05-10 Read SEC document |
| May 04, 2005 Filed May 5, 2005 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.73 | $0.00 |
DisclosureSEC source: 0001179110-05-009036 · edgar.xml · derivative · entry 5 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2014-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest in two equal annual installments beginning on March 23, 2005, the first anniversary date of the grant. Read SEC document |
| May 04, 2005 Filed May 5, 2005 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $38.72 | $116,160.00 |
DisclosureSEC source: 0001179110-05-009036 · edgar.xml · nonDerivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 04, 2005 Filed May 5, 2005 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $38.69 | $386,900.00 |
DisclosureSEC source: 0001179110-05-009036 · edgar.xml · nonDerivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| May 04, 2005 Filed May 5, 2005 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,000 | $38.66 | $657,220.00 |
DisclosureSEC source: 0001179110-05-009036 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| May 04, 2005 Filed May 5, 2005 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,000 | $26.73 | $801,900.00 |
DisclosureSEC source: 0001179110-05-009036 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: All share and dollar amounts reflect a two-for-one stock split made effective on September 3, 2004 benefitting all stockholders as of the record date August 12, 2004. Read SEC document |
| January 26, 2005 Filed May 12, 2005 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-05-009689 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2015-01-26 Read SEC document |
| July 01, 2004 Filed Jul 6, 2004 20:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 208.96 | $67.00 Strike: $67.00 | $14,000.32 |
DisclosureSEC source: 0001179110-04-014349 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208.96 Underlying: Common Stock · 208.96 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over ten years when the reporting person reaches the age of 70. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over ten years when the reporting person reaches the age of 70. Read SEC document |
| May 25, 2004 Filed May 27, 2004 23:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $62.80 | $0.00 |
DisclosureSEC source: 0001179110-04-011735 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2014-05-25 F1 · derivative.exercise_date: Options vest 100% on date of grant. Read SEC document |
| March 23, 2004 Filed Mar 25, 2004 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $53.46 | $0.00 |
DisclosureSEC source: 0001179110-04-006644 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 6,000 shares Expires 2014-03-23 F3 · derivative.exercise_date: Options vest 100% on date of grant. Read SEC document |
| March 23, 2004 Filed Mar 25, 2004 18:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $53.46 | $0.00 |
DisclosureSEC source: 0001179110-04-006644 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2014-03-23 F1 · kind: Granted pursuant to the Gilead Sciences, Inc. 1995 Non-Employee Directors' Stock Option Plan in a transaction exempt from Rule 16b-3. F2 · derivative.exercise_date: Options vest in two equal annual installments beginning on March 23, 2005, the first anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.